wAIHA – A global retrospective chart review to characterise the clinical course of warm autoimmune hemolytic anemia

Lay Description

Autoimmune haemolytic anaemia (AIHA) is a rare condition where the body’s immune system mistakenly attacks and destroys its own red blood cells, causing severe anaemia. The most common form, warm AIHA, makes up 60-70% of cases in adults.

Doctors typically treat it first with corticosteroids; if this doesn’t work, other treatments like removing the spleen or using immunosuppressive drugs are considered.

This global study will look at medical records of patients with warm AIHA to understand how they’re treated in everyday practice, how effective these treatments are, and what complications may arise. The study’s findings could help doctors improve treatment strategies for this condition.

Public Benefit Statement

There are currently no FDA-approved therapies indicated for wAIHA, and patients living with this condition need targeted treatment options with a proven safety and efficacy profile.

There is an ongoing need for further qualitative and quantitive research into the disease to understand the unmet need for novel treatment approaches that address the underlying cause of disease and address the serious health consequences faced by the many people living with wAIHA.